Last reviewed · How we verify
CINTIRORGON
At a glance
| Generic name | CINTIRORGON |
|---|---|
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Study of LYC-55716 in Adult Subjects With Locally Advanced or Metastatic Cancer (PHASE1, PHASE2)
- Study of LYC-55716 With Pembrolizumab in Adult Subjects With Non-Small Cell Lung Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CINTIRORGON CI brief — competitive landscape report
- CINTIRORGON updates RSS · CI watch RSS